À¯¹æ¾Ï ȯÀÚ¿¡°Ô º£Å¸-Â÷´ÜÁ¦ »ç¿ë (Beta-Blocker Use) Ä¡·áÈ¿°ú
ÀÓ»óÁú¹®
|
º£Å¸ Â÷´ÜÁ¦ »ç¿ë (Beta-Block Use)ÀÌ À¯¹æ¾Ï ȯÀÚÀÇ »ç¸ÁÀ²°ú Àç¹ß °¨¼Ò¿¡ È¿°úÀûÀԴϱî?
|
±Ù°Å±â¹Ý´äº¯
|
º£Å¸ Â÷´ÜÁ¦´Â Àü¹ÝÀûÀÎ »ç¸Á (overall deaths, ODs), ¾Ï ƯÁ¤ »ç¸Á (cancer-specific deaths, CSDs) ¶Ç´Â Àç¹ß (recurrences)°ú °ü·ÃÇÏ¿© À¯ÀÍÇÏÁö ¸øÇÏ¿´À½À» º¸°íÇÏ¿´½À´Ï´Ù.
|
¼ÁöÁ¤º¸
|
Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis (2017), Oncology, 2017; 92 ( 5 ) :264-268, DOI: 10.1159/000455143.
|
Áúº´Æ¯¼º
|
º£Å¸ Â÷´ÜÁ¦¸¦ Åõ¿©¹Þ°í ÀÖ´Â À¯¹æ¾Ï ȯÀÚ
(beta-blocker users and non-beta-blocker users)
|
¿¬±¸¼³°è
|
¸ÞŸºÐ¼® (Meta-Analysis)
|
¿¬±¸´ë»ó
|
18,118¸íÀÇ À¯¹æ¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÔ
|
Æò°¡ÁöÇ¥
|
Àü¹ÝÀû »ç¸Á(Overall deaths, ODs)
¾ÏƯÁ¤ »ç¸Á(Cancer-specific deaths (CSDs)
Àç¹ß(recurrences)
|
»ó¼¼¼³¸í
|
18,118 ¸íÀÇ È¯ÀÚ¸¦ Æ÷ÇÔÇÑ 6 °³ÀÇ ¿¬±¸°¡ ºÐ¼®¿¡ ·£´ý È¿°ú ¸ðµ¨(Random-effects model)¿¡¼ º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ¿Í ºñ º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ »çÀÌÀÇ OD Â÷ÀÌ°¡ ¾øÀ½À» ³ªÅ¸³Â´Ù(±³Â÷ºñ´Â 0.87, 95 % ½Å·Ú ±¸°£Àº 0.50-1.52, p = 0.49). 13,782 ¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î 4°ÇÀÇ ¿¬±¸¿¡¼ CSD¸¦ ÃøÁ¤ÇÏ¿´À¸¸ç, º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ¿Í ºñ º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ »çÀÌÀÇ CSD Â÷ÀÌ´Â °íÁ¤ È¿°ú ¸ðµ¨ (Fixed-effect model )À» »ç¿ëÇÏ¿© À¯ÀÇÇÏÁö ¾Ê¾Ò´Ù(OR 0.93, 95 % CI 0.82-1.06, p = 0.29). 3,923 ¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ 3 °ÇÀÇ ¿¬±¸°¡ Àç¹ß¿¡ ´ëÇÑ ºÐ¼®¿¡ Æ÷ÇԵǾú½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î º£Å¸ Â÷´ÜÁ¦´Â Àç¹ß·ü¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê¾ÒÀ½À» º¸°íÇÏ¿´´Ù (OR 0.70, 95 % CI 0.25-1.95, p = 0.49).
|
±Ù°Å¼öÁØ
|
Moderate
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2015 Medical Research Information Center (MedRIC) Editors
|